Clinical Trials

106 enrolled

Colonic Neoplasms

NCT06530251 2026-03-04

A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)

280 enrolled

Carcinoma, Hepatocellular

NCT06353646 2026-02-13

XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer

Phase NA Recruiting

28 enrolled

Pancreatic Neoplasms

NCT07331883 2026-01-21

Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)

35 enrolled

Carcinoma, Hepatocellular

NCT05472948 2025-12-17

Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma

36 enrolled

Appendiceal Neoplasms, Neoplasm Metastasis

NCT07263386 2025-12-04

ARTEMIS-GC3

460 enrolled

Gastric Adenocarcinoma

NCT07157969 2025-12-01

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

300 enrolled

Carcinoma, Hepatocellular

NCT07194005 2025-09-26

Remission

Stomach Neoplasms

NCT06577194 2025-09-19

A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy With IL-2 Followed by Sequential Immunotherapy With CAPOX Combined With PD-1 Antibody and IL-2 for Locally Advanced Rectal Cancer

35 enrolled

Rectal Neoplasms

NCT06031285 2025-07-23

Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial

43 enrolled

Carcinoma, Hepatocellular

NCT06050317 2025-07-22

Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer

25 enrolled

Pancreatic Neoplasms

NCT06329973 2025-07-17

Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer

70 enrolled

Metastatic Gastroesophageal Junction Adenocarcinoma

NCT06356584 2025-06-26

Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases

62 enrolled

Colorectal Neoplasms

NCT07040098 2025-06-26

STELLARIII

228 enrolled

Locally Advanced Rectal Cancer (LARC)

NCT07025889 2025-06-18

IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer

55 enrolled

Stomach Neoplasms

NCT05357846 2025-06-12

PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)

422 enrolled

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT06794086 2025-05-13

SPARKLE-L

24 enrolled

Colorectal Neoplasms

NCT06956716 2025-05-04

Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma

Advanced Intrahepatic Cholangiocarcinoma

NCT06925243 2025-04-22

Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

682 enrolled

Stomach Neoplasms

NCT05713994 2025-03-25

CCGLC-001

Recruiting

300 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06698757 2025-03-13

Different Cycles of Preoperative Neoadjuvant Sintilimab in Mismatch-repair Deficient/microsatellite Instability-high, Locally Advanced Colorectal Cancer

96 enrolled

Colorectal Neoplasms

NCT05010681 2025-02-27

Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer

25 enrolled

Cholangiocarcinoma

NCT05057052 2025-02-27

Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis

25 enrolled

GastrointestinalGynecologic

Liver Metastases

NCT05427487 2025-02-25

Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours

Phase 1 Recruiting

70 enrolled

Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT06841159 2025-02-24

iPULSAR-CRC

116 enrolled

Microsatellite Stable Metastatic Colorectal Cancer

NCT06456515 2025-02-17

Regorafenib and Sintilimab in Combination with Electroacupuncture in MSS CRC

Phase NA Recruiting

Colorectal Neoplasms

NCT06333561 2025-02-06

HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma

Recruiting

300 enrolled

Carcinoma, Hepatocellular

NCT06572813 2025-01-10

CISPD-7

63 enrolled

Pancreatic Neoplasms

NCT06204094 2025-01-07

CASINOs

37 enrolled

Rectal Neoplasms

NCT06761027 2025-01-07

mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer

29 enrolled

Pancreatic Neoplasms

NCT06730373 2024-12-31

First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)

110 enrolled

Stomach Neoplasms

NCT06558227 2024-12-16

Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma

90 enrolled

Carcinoma, Hepatocellular

NCT06709417 2024-11-29

A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)

52 enrolled

Esophageal Squamous Cell Carcinoma

NCT06685276 2024-11-20

Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer

46 enrolled

Colorectal Cancer Metastatic

NCT06313190 2024-11-18

HSBRT2402

140 enrolled

Carcinoma, Hepatocellular

NCT06664996 2024-10-30

Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT

33 enrolled

Carcinoma, Hepatocellular

NCT05495152 2024-10-02

Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma

219 enrolled

Esophageal Squamous Cell Carcinoma

NCT06543836 2024-08-09

ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer

68 enrolled

Colorectal Neoplasms

NCT04636008 2024-08-06

Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer

20 enrolled

Turcot syndrome, Rectal Neoplasms

NCT06403878 2024-05-08

Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer

68 enrolled

Esophageal Neoplasms

NCT06383559 2024-04-25

Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients

39 enrolled

Stomach Neoplasms

NCT06341595 2024-04-02

Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM

40 enrolled

Stomach Neoplasms

NCT05918094 2024-01-26

Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma

540 enrolled

Stomach Neoplasms

NCT06190639 2024-01-05

A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC

31 enrolled

Esophageal Squamous Cell Carcinoma

NCT06091423 2023-11-30

XELOX Combined With Fruquintinib and Sintilimab Regimen Conversion Therapy for Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Only With Liver and/or Retroperitoneal Lymph Node Metastasis, a Prospective Single-arm, Multicenter Study

43 enrolled

Stomach Neoplasms

NCT05992584 2023-09-14

Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC

Carcinoma, Hepatocellular

NCT05608200 2023-05-31

Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC

427 enrolled

Carcinoma, Hepatocellular

NCT05757336 2023-03-07

Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer

50 enrolled

Gallbladder Neoplasms

NCT05236972 2022-12-30

PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer

323 enrolled